Chemotherapy targets

Chemotherapy targets represent a broad category of molecular structures and biological pathways exploited to treat malignancy. Traditional cytotoxic chemotherapy primarily targets the machinery of cell division, including DNA itself, enzymes involved in DNA replication (such as topoisomerases), and structural proteins like tubulin that form the mitotic spindle [3, 9]. These agents generally operate on the principle that rapidly dividing cancer cells are more susceptible to damage than normal cells, although this lack of specificity leads to significant side effects in healthy tissues like bone marrow and the gastrointestinal tract [5, 12]. In modern oncology, the definition of chemotherapy targets has expanded to include specific molecular drivers of cancer, such as mutated tyrosine kinases (e.g., BCR-ABL) and cell surface receptors (e.g., EGFR, HER2) [11, 14]. These targeted therapies aim to interfere with specific signaling pathways required for tumor growth and survival, often offering a wider therapeutic window than traditional cytotoxic agents [10, 13]. Understanding the full spectrum of chemotherapy targets is essential for developing combination regimens and personalized treatment strategies that maximize efficacy while managing systemic toxicity [8, 11].

Other names

Cytotoxic targetsAntineoplastic targetsCancer drug targetsMolecular targets of chemotherapy

Chemotherapy targets are addressed through diverse mechanisms: alkylating agents (e.g., cisplatin) cross-link DNA strands; antimetabolites (e.g., methotrexate) inhibit enzymes like dihydrofolate reductase to block nucleotide synthesis; microtubule inhibitors (e.g., paclitaxel) disrupt the mitotic spindle; and topoisomerase inhibitors (e.g., etoposide) prevent DNA untwisting during replication [1, 4, 9].